Skip to main content
SpringerLink
Log in

ASCO update 2016: colorectal cancer

  • original report
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

At this year’s annual meeting of the American Society of Clinical Oncology, held during 3–7 June 2016 in Chicago, USA, investigators discussed the latest findings in colorectal cancer research. The main topics were immune checkpoint inhibition therapy in colorectal cancer and the prognostic and predictive influence of sidedness in the primary tumor location.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O’Neil J, Shaw JE, Atkins JN, Horvath LE, Polite BN, Meyerhardt JA, O’Reilly EM, Goldberg RM, Hochster HS, Blanke CD, Schilsky RL, Mayer RJ, Bertagnolli MM, Lenz H‑J. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34(suppl):abstr 3504.

    Article  Google Scholar 

  2. Venook AP, Niedzwiecki D, Lenz H‑J, Innocenti F, Mahoney MR, O’Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Schilsky RL, Bertagnolli MM, Blanke CD. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014;32(suppl):abstr LBA3.

    Article  Google Scholar 

  3. Heinemann V, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S‑E, Heintges T, Lerchenmuller CA, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen CA, Jung A, Kirchner T, Stintzing S. Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol. 2014;32(suppl):abstr 3600.

    Article  Google Scholar 

  4. Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Wong R, Kosmider S, Tran B, Desai T, Hayes TM, Haydon AM, Yip D, Christie M, Strausberg R, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers. J Clin Oncol. 2016;34(suppl):abstr 3511.

    Article  Google Scholar 

  5. Overman MJ, Kopetz S, McDermott RS, Leach J, Lonardi S, Lenz H‑J, Morse MA, Desai J, Hill A, Axelson MD, Moss RA, Lin C‑S, Goldberg M, Andre T. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J Clin Oncol. 2016;34(suppl):abstr 3501.

    Article  Google Scholar 

  6. Bendell JC, Kim TW, Goh BC, Wallin J, Oh D‑Y, Han S‑W, Lee CB, Hellmann MD, Desai J, Lewin JH, Solomon BJ, Chow LQM, Miller WH, Gainor JF, Flaherty K, Infante JR, Das-Thakur M, Foster P, Cha E, Bang Y‑J. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). J Clin Oncol. 2016;34(suppl):abstr 3502.

    Article  Google Scholar 

  7. Le DT, Uram JN, Wang H, Bartlett B, kemberling H, Eyring A, Azad NS, Laheru D, Donehower RC, Crocenzi TS, Goldberg RM, Fisher GA, Lee JJ, Greten TF, Koshiji M, Kang SMP, Anders RA, Eshleman JR, Vogelstein B, Diaz LA. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. J Clin Oncol. 2016;34(suppl):abstr 103.

    Article  Google Scholar 

  8. Raghav RPS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Kee BK, Muranyi A, Singh S, Routbort M, Chen K, Shaw KR, Shannmugam K, Maru DM, Fakih M, Kopetz S. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol. 2016;34(suppl):abstr 3517.

    Article  Google Scholar 

  9. Siena S, Sartore-Bianchi A, Lonardi S, Trusolino L, Martino C, Bencardino K, Leone F, Zagonel V, Valtorta E, Torri V, Siravegna G, Amatu A, Bonazzina EF, Rusconi F, Ghezzi S, Ciardiello F, Veronese S, Comoglio PM, Bardelli A, Marsoni S. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. J Clin Oncol. 2015;33(suppl):abstr 3508.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Hämatologie und Internistische Onkologie, Rheumatologie und Infektiologie, Klinikum Klagenfurt am Wörthersee, Feschnigstraße 11, 9020, Klagenfurt, Austria

    Wolfgang Eisterer

Authors
  1. Wolfgang Eisterer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Eisterer.

Ethics declarations

Conflict of interest

W. Eisterer declares that he has no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eisterer, W. ASCO update 2016: colorectal cancer. memo 9, 222–225 (2016). https://doi.org/10.1007/s12254-016-0298-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-016-0298-9

Keywords

Search

Navigation